What is Zacks Research’s Forecast for TBPH Q2 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Stock analysts at Zacks Research raised their Q2 2026 earnings estimates for shares of Theravance Biopharma in a note issued to investors on Monday, January 13th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of ($0.11) for the quarter, up from their previous forecast of ($0.12). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. During the same period in the previous year, the business posted ($0.17) EPS.

Theravance Biopharma Stock Up 1.7 %

NASDAQ:TBPH opened at $8.58 on Thursday. The company has a market capitalization of $421.88 million, a PE ratio of -8.50 and a beta of 0.21. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.44. The stock’s 50 day moving average price is $9.46 and its 200 day moving average price is $8.89.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in Theravance Biopharma in the 3rd quarter valued at about $60,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Theravance Biopharma in the second quarter valued at approximately $108,000. Ballentine Partners LLC purchased a new stake in shares of Theravance Biopharma during the third quarter worth approximately $104,000. Finally, XTX Topco Ltd acquired a new stake in shares of Theravance Biopharma during the second quarter worth $129,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.